MedTrace Logo

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

NCT03168737 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-15

No results posted yet for this study

Summary

This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors. Using 18F-fluoroazomycin arabinoside with PET-CT may help doctors plan better treatment for patients with solid tumors. 18F-fluoroazomycin arabinoside may help to show how much oxygen is present in a tumor during a PET-CT scan.

Conditions

  • Malignant Breast Neoplasm
  • Malignant Colorectal Neoplasm
  • Malignant Pancreatic Neoplasm
  • Malignant Solid Neoplasm

Interventions

PROCEDURE

Computed Tomography

Undergo PET-CT scan

RADIATION

Fluorine F 18-fluoroazomycin Arabinoside

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET-CT scan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Franklin C Wong · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168737 on ClinicalTrials.gov